CompanyAZNNYSECambridge

AstraZeneca

AstraZeneca is a pharmaceutical company based in the United Kingdom that develops medicines across oncology, cardiovascular, respiratory, immunology, and rare disease areas through small molecules and biologics.

Stories only

SEC EDGAR ClinicalTrials.gov astrazeneca.com

8-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

HUTCHMED, AstraZeneca file US NDA for Orpathys plus Tagrisso in MET-driven lung cancer

Sep 29Regulatory decisionAstraZeneca Hutchmed

AstraZeneca completes Phase 1 laroprovstat/ezetimibe bioavailability study in healthy adults

Sep 28Weekly roundup, 2 itemsacalabrutinib AstraZeneca

AstraZeneca-linked studies: OlympiaN, ZEAL and CHIO3 post results; two new studies registered

Sep 25Weekly roundup, 7 itemsAstraZeneca AZD0120

HUTCHMED details ESMO 2026 slots for SAFFRON, SANOVO Phase III lung cancer data

Sep 24PublicationAstraZeneca Hutchmed

AstraZeneca's Trixeo approved in EU for asthma maintenance treatment

Sep 23Regulatory decisionAstraZeneca budesonide, glycopyrrolate, and formoterol fumarate

CHMP backs two AstraZeneca drugs: Klygefa in gMG, Enhertu in early breast cancer

Sep 21Regulatory milestoneAstraZeneca fam-trastuzumab deruxtecan-nxki

AstraZeneca registers Phase 3 ovarian cancer ADC trial and Phase 1 hMPV antibody study

Sep 17Weekly roundup, 3 itemsAstraZeneca AZD0543

FDA approves supplemental efficacy application for AstraZeneca's Truqap

Sep 16Regulatory decisionAstraZeneca capivasertib

AstraZeneca's SERENA-4 trial misses main goal for Etcamah in first-line breast cancer

Sep 14Clinical readoutAstraZeneca camizestrant

FDA approves two Tagrisso supplements for AstraZeneca

Sep 14Regulatory decisionAstraZeneca osimertinib

AstraZeneca posts CAPItello-281 results in PTEN-deficient prostate cancer; registers AZD4954 Phase 1

Sep 10Weekly roundup, 2 itemsAstraZeneca AZD4954

FDA approves AstraZeneca's Etcamah for HR-positive breast cancer

Sep 8Regulatory decisionAstraZeneca camizestrant

FDA drug application records confirm Etcamah approval details, dosage form

Sep 4Regulatory decisionAstraZeneca camizestrant

AstraZeneca week: Imfinzi label update, ASSURE CLL results posted, four trials registered

Sep 3Weekly roundup, 6 itemsacalabrutinib AstraZeneca

August 2026

EU clears Enhertu plus pertuzumab as first-line HER2-positive metastatic breast cancer therapy

Aug 31Regulatory decisionAstraZeneca fam-trastuzumab deruxtecan-nxki

Tezspire meets primary endpoints in Phase III EoE trial CROSSING

Aug 27Clinical readoutAmgen AstraZeneca

AstraZeneca posts MITCHELL asthma results; registers AZD6234 Phase 3 SELENE 2

Aug 27Weekly roundup, 7 itemsAstraZeneca AZD4144

AstraZeneca adds fourth trial: Phase 3 AZD6234 in obesity, adjunct to incretins

Aug 21Weekly roundup, 4 itemsAstraZeneca AZD0292

HUTCHMED and AstraZeneca report positive Phase III SAFFRON data in EGFR-mutated lung cancer

Aug 17Clinical readoutAstraZeneca Hutchmed

AstraZeneca halts eVOLVE-Lung02 trial of volrustomig in lung cancer

Aug 17Clinical readoutAstraZeneca volrustomig

Pipeline by stage

Phase 3 primary completions, next 6 months

Oct 2026benralizumabasthma · NCT03953300

Oct 2026budesonide, glycopyrrolate, and formoterol fumaratemoderate to severe copd · NCT06531798

Oct 2026capivasertibbreast cancer · NCT06635447

Oct 2026breast cancerNCT06429761

Nov 2026anifrolumab-fniacutaneous lupus erythematosus · NCT06015737

Nov 2026breast cancer; her2-positive; metastaticNCT04784715

Details

Headquarters: Cambridge
Incorporated: United Kingdom
Industry: Pharmaceutical Preparations
Formerly: ZENECA GROUP PLC (to 1999)
Also known as: Acerta Pharma, ALEXION PHARM, Alexion Pharmaceuticals, Amolyt Pharma, and 11 more
Astra Zeneca, ASTRAZENECA AB, AstraZeneca Global R&D (Beijing) Co., Ltd., AstraZeneca Global R&D (China) Co., Ltd., ASTRAZENECA PLC, ASTRAZENECA UK LTD, AZN, Fusion Pharmaceuticals, Gracell Biotechnologies, Icosavax, MedImmune

How the company describes itself